Table 2 Clinical data of the studied groups
Variable | Control N = 150 | Total studied CKD patients (n = 150) | P1 | Stage I-II N = 45 | Stage III-IV N = 50 | Stage V N = 55 | P2 |
|---|---|---|---|---|---|---|---|
Fracture prevalence | 0 (0%) | 4 (2.7%) | 0.07 | 0(0%) | 1(2%) | 3 (5.5%) | 0.06 |
Menopaused femlaes | 7 (4.7%) | 8 (5.3%) | 0.06 | 2 (4.4%) | 3(6%) | 3 (5.5%) | 0.07 |
Use of vitamin D analouge | 10 (6.7%) | 32 (21.3%) | 0.58 | 3 (6.7%) | 5 (10%) | 24 (43.6%) | 0.06 |
Use of phosphate binder | 0 (0%) | 15 (10%) | 0.67 | 0 (0%) | 5 (10%) | 10 (18.2%) | 0.57 |